Microtubule-mediated NF-κB activation in the TNF-α signaling pathway

Experimental Cell Research

Volumn 315, Issue 19, 2009, Pages 3242-3249

  Jackman, Robert W ^a   Rhoads, Mary G ^a   Cornwell, Evangeline ^a   Kandarian, Susan C ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

Colchicine; Cytoskeleton; Myotubes; Taxol; TNF receptor

Indexed keywords

ANDROGRAPHOLIDE; CHEMOKINE; COLCHICINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HELENALIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PACLITAXEL; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; VINBLASTINE; WEDELOLACTONE;

ANIMAL CELL; ARTICLE; CELL DIVISION; CELL MOTILITY; CONTROLLED STUDY; CYTOLOGY; CYTOSKELETON; GENE TARGETING; HUMAN; HUMAN CELL; MICROTUBULE; MOUSE; MYOTUBE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INDUCTION; SCIENTIFIC LITERATURE; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 70350409237     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2009.08.020     Document Type: Article

References (24)

1. Janmey P.A. The cytoskeleton and cell signaling: component localization and mechanical coupling. Physiol. Rev. 78 (1998) 763-781
2. Gardner M.K., Hunt A.J., Goodson H.V., and Odde D.J. Microtubule assembly dynamics: new insights at the nanoscale. Curr. Opin. Cell Biol. 20 (2008) 64-70
3. Jordan M.A., and Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4 (2004) 253-265
4. Gilmore T.D. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 25 (2006) 6680-6684
5. Jung Y.J., Isaacs J.S., Lee S., Trepel J., and Neckers L. Microtubule disruption utilizes an NFkappa B-dependent pathway to stabilize HIF-1alpha protein. J. Biol. Chem. 278 (2003) 7445-7452
6. Cvetkovic I., Miljkovic D., Vuckovic O., Harhaji L., Nikolic Z., Trajkovic V., and Mostarica Stojkovic M. Taxol activates inducible nitric oxide synthase in rat astrocytes: the role of MAP kinases and NF-kappaB. Cell Mol. Life Sci. 61 (2004) 1167-1175
7. Hunter R.B., Stevenson E., Koncarevic A., Mitchell-Felton H., Essig D.A., and Kandarian S.C. Activation of an alternative NF-kappaB pathway in skeletal muscle during disuse atrophy. FASEB J. 16 (2002) 529-538
8. Wang D., and Baldwin Jr. A.S. Activation of nuclear factor-kappaB-dependent transcription by tumor necrosis factor-alpha is mediated through phosphorylation of RelA/p65 on serine 529. J. Biol. Chem. 273 (1998) 29411-29416
9. Cai D., Frantz J.D., Tawa Jr. N.E., Melendez P.A., Oh B.C., Lidov H.G., Hasselgren P.O., Frontera W.R., Lee J., Glass D.J., and Shoelson S.E. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 119 (2004) 285-298
10. Rosette C., and Karin M. Cytoskeletal control of gene expression: depolymerization of microtubules activates NF-kappa B. J. Cell Biol. 128 (1995) 1111-1119
11. Xia Y.F., Ye B.Q., Li Y.D., Wang J.G., He X.J., Lin X., Yao X., Ma D., Slungaard A., Hebbel R.P., Key N.S., and Geng J.G. Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50. J. Immunol. 173 (2004) 4207-4217
12. Lyss G., Knorre A., Schmidt T.J., Pahl H.L., and Merfort I. The anti-inflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-kappaB by directly targeting p65. J. Biol. Chem. 273 (1998) 33508-33516
13. Kobori M., Yang Z., Gong D., Heissmeyer V., Zhu H., Jung Y.K., Gakidis M.A., Rao A., Sekine T., Ikegami F., Yuan C., and Yuan J. Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK complex. Cell Death Differ. 11 (2004) 123-130
14. Leung T.H., Hoffmann A., and Baltimore D. One nucleotide in a kappaB site can determine cofactor specificity for NF-kappaB dimers. Cell 118 (2004) 453-464
15. Hayden M.S., and Ghosh S. Shared principles in NF-kappaB signaling. Cell 132 (2008) 344-362
16. Basseres D.S., and Baldwin A.S. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25 (2006) 6817-6830
17. Jackman R.W., and Kandarian S.C. The molecular basis of skeletal muscle atrophy. Am. J. Physiol. Cell Physiol. 287 (2004) C834-C843
18. Ladner K.J., Caligiuri M.A., and Guttridge D.C. Tumor necrosis factor-regulated biphasic activation of NF-kappa B is required for cytokine-induced loss of skeletal muscle gene products. J. Biol. Chem. 278 (2003) 2294-2303 Electronic publication 2002 Nov 12
19. Hunter R.B., and Kandarian S.C. Disruption of either the Nfkb1 or the Bcl3 gene inhibits skeletal muscle atrophy. J. Clin. Invest. 114 (2004) 1504-1511
20. Wajant H., Pfizenmaier K., and Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 10 (2003) 45-65
21. Baud V., and Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends. Cell Biol. 11 (2001) 372-377
22. Idriss H.T., and Naismith J.H. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc. Res. Tech. 50 (2000) 184-195
23. Birbach A., Gold P., Binder B.R., Hofer E., de Martin R., and Schmid J.A. Signaling molecules of the NF-kappa B pathway shuttle constitutively between cytoplasm and nucleus. J. Biol. Chem. 277 (2002) 10842-10851
24. Mikenberg I., Widera D., Kaus A., Kaltschmidt B., and Kaltschmidt C. TNF-alpha mediated transport of NF-kappaB to the nucleus is independent of the cytoskeleton-based transport system in non-neuronal cells. Eur. J. Cell Biol. 85 (2006) 529-536